Company announcement no. 6-2018
Birkerød, 20 August 2018
ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has completed the development and regulatory approval of its suPARnostic® TurbiLatex product.
The suPARnostic® TurbiLatex product has initially been developed and approved for the Roche Diagnostics cobas C 111 analyzer. Roche Diagnostics is the market leader in the clinical chemistry area in the hospital markets in Europe and offers integrated diagnostic solutions on its cobas platforms.
The launch of the cobas C 111 application is the first step in providing products for the Roche Diagnostics platform. Next step is to validate the suPARnostic® TurbiLatex on the higher throughput instruments such as the cobas c 500 and c 700 series that are most commonly used in diagnostic laboratories. suPARnostic® Turbilatex enables automatic handling of blood samples at central laboratories, and is thus a pivotal element in the company’s European expansion strategy with special focus on the acute care market.
CEO Jakob Knudsen, says in a comment: ”We are very pleased, that we have been able to develop and launch our first application of our suPARnostic® TurbiLatex product line. The suPARnostic® TurbiLatex product is pivotal in relation to our growth strategy in the emergency department market since it allows the medical professionals to obtain results in exactly the same manner that most other blood parameters are reported. This means, that our customers will be able to obtain suPAR measurements at the same time as they receive most other diagnostic data thereby facilitating efficient decision making”.
About the turbidimetric measurement principle: The TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. The principle of measuring blood samples by using turbidimetry is very important in relation to immunoassays, as it is the basis for almost all central laboratory clinical chemistry instrument platforms in hospitals.
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com
ViroGates A/S
CVR-nr. 25734033, Blokken 45, DK-340 Birkerød
www.virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
About ViroGates
ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.
Attachment
